Cannabis L. (Cannabis sativa)
Influence of cannabidiol on secobarbital effects and plasma kinetics CSV JSON

To investigate the possible metabolic interaction between cannabidiol (CBD) and secobarbital, 6 male volunteers received 150 mg/70 kg sodium secobarbital orally immediately after smoking a marihuana cigarette prepared to deliver 0, 150, or 500 µg/kg CBD. The study was performed in a double-blind manner with each of the three treatments being assigned to every subject. Clinical effects and plasma secobarbital concentrations were recorded at periodic intervals. CBD did not alter the summary parameters which describe the secobarbital plasma concentration time curve. Secobarbital half-life, peak concentration, time of peak concentration, and area under the curve were unchanged by the coadministration of CBD. Clinical effects of secobarbital were also unaltered by CBD pretreatment. Thus at the doses administered, CBD does not appear to inhibit secobarbital metabolism in man.

1 . Secobarbital Plasma Concentrations Following Sodium Secobarbital Ingestion and 500 µg/kg CBD Pretreatment (id=NPDI-SCT2WA)

In Vivo Interaction Study

No Effect (based on bioequivalence limits) was detected.

secobarbital

Figure 1

Results

Values estimated from Figure 1. Original value was converted to ng/mL: Cmax (µg/mL): 2.75

Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Double-blind
Placebo-controlled
Single dosing

Population

Healthy volunteers
Males

6

"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."

Pharmacokinetic (PK) Sampling Information

0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h

Drug or Natural Product Administration

Object Administration — secobarbital

Oral

Capsule

150 mg/70 kg

Once

Precipitant Administration — delta-9-tetrahydrocannabinol (THC)

Inhalation

Cigarette

500 µg/kg

Once

Natural Product Characteristics

Not specified

2 . Secobarbital Plasma Concentrations Following Sodium Secobarbital Ingestion and 150 µg/kg CBD Pretreatment (id=NPDI-noOe3w)

In Vivo Interaction Study

No Effect (based on bioequivalence limits) was detected.

secobarbital

Figure 1

Results

Values estimated from Figure 1 and converted from µg/mL. Original estimated value: 2.5 µg/mL.

Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Double-blind
Placebo-controlled
Single dosing

Population

Healthy volunteers
Males

6

"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."

Pharmacokinetic (PK) Sampling Information

0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h

Drug or Natural Product Administration

Object Administration — secobarbital

Oral

Capsule

150 mg/70 kg

Once

Precipitant Administration — delta-9-tetrahydrocannabinol (THC)

Inhalation

Cigarette

150 µg/kg

Once

Natural Product Characteristics

Not specified

3 . Plasma Concentrations of Secobarbital After Placebo Pretreatment and Oral Administration of Secobarbital (id=NPDI-tUG7XA)

In Vivo Interaction Study

No Effect (based on bioequivalence limits) was detected.

secobarbital

placebo

Table 1.

Results

Values converted from µg/mL. 
Original value: Cmax (µg/mL): 2.59 ± 0.94
Table 1.

Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Double-blind
Placebo-controlled
Single dosing

Population

Healthy volunteers
Males

6

"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."

Pharmacokinetic (PK) Sampling Information

0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h

Drug or Natural Product Administration

Object Administration — secobarbital

Oral

Capsule

150 mg/70 kg

Once

Precipitant Administration — placebo

Inhalation

Cigarette

0 mg

Once

Natural Product Characteristics

Not specified